Cerus Corporation - Common Stock (CERS)
Frequently Asked Questions About Cerus Corporation - Common Stock (CERS)
Are there any notable achievements by Cerus Corporation?
Cerus Corporation has received multiple awards and recognitions over the years for its innovation in blood safety and its contributions to transfusion medicine. The INTERCEPT Blood System has been lauded for helping reduce transfusion-related infections, making it a key solution in the healthcare industry.
Does Cerus Corporation conduct research and development?
Yes, Cerus Corporation invests heavily in research and development to advance its blood safety technologies and expand its product offerings. The R&D program focuses on developing new applications for the INTERCEPT Blood System and exploring additional therapeutic uses.
How can investors learn more about Cerus Corporation?
Investors can learn more about Cerus Corporation by visiting the company's official website, reviewing its financial reports, and following corporate announcements. Additionally, many financial news platforms offer insights and analyses of the company's stock performance and market trends.
How does Cerus Corporation address global health challenges?
Cerus Corporation directly addresses global health challenges by providing solutions that reduce the risks associated with transfusion-transmitted infections, particularly in regions where blood safety is a critical concern. Its technologies are designed to meet the needs of diverse healthcare systems, benefiting patients worldwide.
How does Cerus Corporation ensure the safety of its products?
Cerus Corporation ensures the safety and efficacy of its products through rigorous clinical trials, adherence to stringent regulatory standards, and ongoing quality assurance processes. The company continuously monitors its products in the market to maintain compliance and improve safety features.
Is Cerus Corporation a publicly traded company?
Yes, Cerus Corporation is publicly traded on the Nasdaq stock exchange under the ticker symbol 'CERS'. The company’s stock performance can be monitored through various financial news platforms and stock market tracking tools.
Is the INTERCEPT Blood System approved by regulatory agencies?
Yes, the INTERCEPT Blood System has received regulatory approval in various countries worldwide. It is approved for use in the United States by the Food and Drug Administration (FDA) and has also been granted CE Mark approval in Europe, allowing it to be marketed within the European Union.
What are the financial highlights of Cerus Corporation?
Cerus Corporation has demonstrated growth in recent years, with increasing revenue driven by product sales and expanding adoption of the INTERCEPT Blood System. The company provides quarterly financial reports to investors, highlighting revenue, expenses, and key financial metrics to inform stakeholders.
What does Cerus Corporation do?
Cerus Corporation is a biomedical products company focused on developing and commercializing innovative blood safety solutions. Its primary product is the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections, thereby enhancing the safety of blood transfusions for patients.
What is Cerus Corporation's approach to sustainability?
Cerus Corporation is committed to sustainability by operating in a manner that minimizes its environmental impact while advancing health outcomes. The company focuses on responsible manufacturing practices and aims to enhance healthcare practices without compromising ecological standards.
What is the company's mission?
Cerus Corporation's mission is to enhance the safety of blood transfusions worldwide by providing innovative blood safety solutions that minimize the risk of transfusion-related infections and improve overall patient outcomes in transfusion medicine.
What is the future outlook for Cerus Corporation?
The future outlook for Cerus Corporation appears promising, with ongoing advancements in its blood safety technologies and potential expansion into new markets. The company aims to further enhance the adoption of its INTERCEPT Blood System, while exploring new applications and beneficial collaborations within the healthcare sector.
What is the INTERCEPT Blood System?
The INTERCEPT Blood System is Cerus Corporation's flagship product which utilizes a proprietary technology to inactivate pathogens in blood components such as red blood cells, platelets, and plasma. This system significantly reduces the risk of bacterial, viral, and parasitic infections in blood transfusions.
What is the target customer base for Cerus Corporation?
Cerus Corporation primarily targets blood banks, transfusion medicine services, and hospitals. These institutions are focused on ensuring blood safety and seek effective solutions for pathogen inactivation to protect patients receiving transfusions.
What markets does Cerus Corporation serve?
Cerus Corporation serves the global blood banking and transfusion markets. Its products are vital for hospitals, blood centers, and other healthcare facilities that require safe and reliable blood products for patient transfusions, particularly in high-risk populations.
What partnerships does Cerus Corporation engage in?
Cerus Corporation actively seeks partnerships with blood centers, healthcare organizations, and research institutions to enhance its product development and expand its market presence. Collaboration with these entities facilitates research, pilot programs, and potential market entry for new initiatives.
When was Cerus Corporation founded?
Cerus Corporation was founded in 1991. Since its inception, the company has focused on leveraging its proprietary technology platforms to provide innovative solutions to transfusion medicine and improve patient outcomes.
Where is Cerus Corporation headquartered?
Cerus Corporation is headquartered in Concord, California, USA. The company's location allows it to effectively engage in research, development, and commercial activities while closely collaborating with regulatory bodies and healthcare providers.
Who are Cerus Corporation's competitors?
Cerus Corporation competes with various companies in the blood safety market, including those developing pathogen reduction technologies and blood processing systems. Major competitors include Grifols, Terumo BCT, and BioPorto, among others.
What is the current price of Cerus Corporation - Common Stock?
The current price of Cerus Corporation - Common Stock is 1.355
When was Cerus Corporation - Common Stock last traded?
The last trade of Cerus Corporation - Common Stock was at 2:00 pm EDT on April 22nd, 2025
What is the market capitalization of Cerus Corporation - Common Stock?
The market capitalization of Cerus Corporation - Common Stock is 244.65M
How many shares of Cerus Corporation - Common Stock are outstanding?
Cerus Corporation - Common Stock has 180.55M shares outstanding.